User profiles for P. Giannakakou

Paraskevi Giannakakou

Professor of pharmacology in Medicine, Weill Cornell
Verified email at med.cornell.edu
Cited by 17785

Targeting microtubules for cancer chemotherapy

J Zhou, P Giannakakou - Current Medicinal Chemistry-Anti …, 2005 - ingentaconnect.com
Chemical compounds that interfere with microtubules such as the vinca alkaloids and taxanes
are important chemotherapeutic agents for the treatment of cancer. As our knowledge of …

The importance of p53 location: nuclear or cytoplasmic zip code?

A O'Brate, P Giannakakou - Drug resistance updates, 2003 - Elsevier
The regulation of p53 functions is tightly controlled through several mechanisms including
p53 transcription and translation, protein stability, post-translational modifications, and …

Androgen receptor on the move: boarding the microtubule expressway to the nucleus

M Thadani-Mulero, DM Nanus, P Giannakakou - Cancer research, 2012 - AACR
Recent studies have shown that the microtubule-stabilizing drug paclitaxel, which is commonly
used for the treatment of prostate cancer, inhibits signaling from the androgen receptor by …

Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation

…, JR Cubillos-Ruiz, G Galletti, P Giannakakou… - Nature cell …, 2018 - nature.com
The heterogeneity of exosomal populations has hindered our understanding of their biogenesis,
molecular composition, biodistribution and functions. By employing asymmetric flow field…

[HTML][HTML] Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization

P Giannakakou, DL Sackett, YK Kang, Z Zhan… - Journal of Biological …, 1997 - ASBMB
Acquired resistance to paclitaxel can be mediated by P-glycoprotein or by alterations
involving tubulin. We report two paclitaxel-resistant sublines derived from 1A9 human ovarian …

[PDF][PDF] 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF

…, MT Willard, H Zhong, JW Simons, P Giannakakou - Cancer cell, 2003 - cell.com
… Lanes P contain the polymerized form of tubulin and lanes S contain the depolymerized
soluble form of tubulin. The percent- … This analysis revealed a significant decrease (p

Synthesis of epothilones A and B in solid and solution phase

…, Y He, D Vourloumis, Z Yang, T Li, P Giannakakou… - Nature, 1997 - nature.com
letters to nature Page 1 letters to nature magnetoresistive component in CMR materials
arising at grain boundaries at high temperatures. Our highly symmetric Wheatstone-bridge …

[HTML][HTML] Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol®)

RJ Kowalski, P Giannakakou, E Hamel - Journal of Biological Chemistry, 1997 - ASBMB
Epothilones A and B, natural products with minimal structural analogy to taxoids, have effects
similar to those of paclitaxel (Taxol®) in cultured cells and on microtubule protein, but differ …

A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells

P Giannakakou, R Gussio, E Nogales… - Proceedings of the …, 2000 - National Acad Sciences
… The percent of polymerized tubulin (% P) was determined by dividing the densitometric value
of polymerized tubulin by the total tubulin content (the sum of P plus S). The results shown …

Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer

…, ST Tagawa, NH Bander, DM Nanus, P Giannakakou - Cancer research, 2011 - AACR
Prostate cancer progression requires active androgen receptor (AR) signaling which occurs
following translocation of AR from the cytoplasm to the nucleus. Chemotherapy with taxanes …